

**Date: October 17, 2024**

**BSE Limited**  
P J Towers,  
Dalal Street,  
Mumbai – 400 001

**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Script Code: 543904**

**Symbol: MANKIND**

Dear Sir/ Madam,

**Subject: Commercial Papers**

---

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation to our letter dated September 30, 2024, the Company has issued the following Commercial Papers;

1. 60,000 listed, rated, transferable, rupee denominated Commercial Paper having a face value of INR 5,00,000 each, aggregating up to INR 30,00,00,00,000 (CP Series 1);
2. 10,000 listed, rated, transferable, rupee denominated Commercial Paper having a face value of INR 5,00,000 each, aggregating up to INR 5,00,00,00,000 (CP Series 2);and
3. 30,000 listed, rated, transferable, rupee denominated Commercial Paper having a face value of INR 5,00,000 each, aggregating up to INR 15,00,00,00,000 (CP Series 3).

The detailed disclosures in respect of Commercial Paper is enclosed as Annexure I.

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

**Pradeep Chugh**  
**Company Secretary and Compliance Officer**

**Annexure I**

Sr. No.	Particulars	CP Series 1	CP Series 2	CP Series 3
1.	Maximum Settlement amount Size	INR 30,000,000,000	INR 5,00,00,00,000	INR 15,00,00,00,000
2.	Whether proposed to be listed? If yes, name of the stock exchange	BSE Limited		
3.	Tenure of the instrument	91 days	182 days	365 days
4.	Date of Allotment	17/10/2024	17/10/2024	17/10/2024
5.	Date of Maturity	16/01/2025	17/04/2025	17/10/2025
6.	Coupon/Interest offered	Zero Rate		
7.	Schedule of payment of coupon/interest and principal	Upfront discount @ 7.45% p.a.	Upfront discount @ 7.65% p.a.	Upfront discount @ 7.85% p.a.
8.	Charge/security, if any, created over the assets	Not applicable		
9.	Special rights/interest/privileges attached to the instrument and changes thereof	Not applicable		
10.	Delay in payment of interest/ principal amount for a period of more than 3 months from the due date or default in payment of interest/principal	Not Applicable		
11.	Details of any letter or comments regarding payment/non-payment of interest, principal on due dates, or any other matter concerning the security and/or the assets along with its comments thereon, if any	Not Applicable		

**MANKIND PHARMA LIMITED**